Julia Harris

2.4k total citations · 2 hit papers
21 papers, 1.5k citations indexed

About

Julia Harris is a scholar working on Rheumatology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Julia Harris has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Rheumatology, 5 papers in Infectious Diseases and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Julia Harris's work include Systemic Lupus Erythematosus Research (6 papers), Pulmonary Hypertension Research and Treatments (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Julia Harris is often cited by papers focused on Systemic Lupus Erythematosus Research (6 papers), Pulmonary Hypertension Research and Treatments (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Julia Harris collaborates with scholars based in United States, United Kingdom and Germany. Julia Harris's co-authors include Vallerie V. McLaughlin, Jean‐Luc Vachiéry, Jonathan Langley, Lewis J. Rubin, Gérald Simonneau, Karen Miller, Adaani Frost, Hossein Ardeschir Ghofrani, Christiana Blair and Marius M. Hoeper and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Julia Harris

18 papers receiving 1.5k citations

Hit Papers

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Ar... 2014 2026 2018 2022 2015 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
    2015 750 citations Nazzareno Galiè, Joan Albert Barberà et al. New England Journal of Medicine profile →
  2. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    2014 350 citations Bonaventura Clotet, Judith Feinberg et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julia Harris United States 11 868 556 354 275 193 21 1.5k
Adriano Pellicelli Italy 21 201 0.2× 311 0.6× 190 0.5× 62 0.2× 628 3.3× 59 1.3k
Katsuyuki Fukutake Japan 19 193 0.2× 70 0.1× 109 0.3× 59 0.2× 66 0.3× 139 1.9k
Rachid Agher France 18 134 0.2× 45 0.1× 519 1.5× 433 1.6× 238 1.2× 33 1.1k
Corentin Richard France 22 296 0.3× 34 0.1× 185 0.5× 97 0.4× 98 0.5× 71 1.7k
H Beaufils France 18 242 0.3× 37 0.1× 162 0.5× 66 0.2× 186 1.0× 69 1.1k
A Cipriani Italy 25 869 1.0× 44 0.1× 137 0.4× 110 0.4× 403 2.1× 59 1.6k
Stefania Cocchi Italy 18 368 0.4× 78 0.1× 202 0.6× 24 0.1× 284 1.5× 63 944
William E. Beschorner United States 9 103 0.1× 111 0.2× 67 0.2× 39 0.1× 176 0.9× 11 1.1k
Maureen Reiner United States 22 254 0.3× 25 0.0× 113 0.3× 62 0.2× 153 0.8× 51 1.4k
Jean-Paul Battesti France 11 365 0.4× 37 0.1× 235 0.7× 115 0.4× 125 0.6× 12 767

Countries citing papers authored by Julia Harris

Since Specialization
Citations

This map shows the geographic impact of Julia Harris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Harris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Harris more than expected).

Fields of papers citing papers by Julia Harris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Harris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Harris. The network helps show where Julia Harris may publish in the future.

Co-authorship network of co-authors of Julia Harris

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Harris. A scholar is included among the top collaborators of Julia Harris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Harris. Julia Harris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manzi, Susan, Jorge Sánchez‐Guerrero, Naoto Yokogawa, et al.. (2025). The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis. Lupus. 34(7). 666–678.
2.
Mosca, Marta, Joan T. Merrill, Stuart Bloom, et al.. (2024). POS0530 BELIMUMAB REDUCES DISEASE FLARES VERSUS PLACEBO IN ADULTS WITH EARLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS. Annals of the Rheumatic Diseases. 83. 968–969.
3.
Thomson, Nicholas D., et al.. (2024). Alcohol perceptions and driving decisions among adolescents: Exploring the role of peer and parental influences in Virginia. Traffic Injury Prevention. 26(4). 383–388. 1 indexed citations
4.
Volkmann, Ingo, et al.. (2022). Der schwerwiegendste Vorfall – Erfahrungen von Aggressionen und Gewalt in der Augenheilkunde. Die Ophthalmologie. 119(9). 937–944.
5.
Sheikh, Saira Z., James Cheng‐Chung Wei, Dana Tegzová, et al.. (2022). POS0712 YEAR-4 OBSERVATIONAL FOLLOW-UP OF BELIMUMAB SAFETY (MORTALITY AND MALIGNANCIES) IN PATIENTS WITH SLE WHO COMPLETED A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED SAFETY STUDY. Annals of the Rheumatic Diseases. 81. 637–638. 1 indexed citations
6.
Petri, Michelle, Helain J. Landy, Megan E. B. Clowse, et al.. (2022). Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Annals of the Rheumatic Diseases. 82(2). 217–225. 19 indexed citations
7.
Scheinberg, Morton, James Cheng‐Chung Wei, Dana Tegzová, et al.. (2021). AB0288 SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: YEAR 2 FOLLOW-UP OF A LARGE PHASE 4, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. Annals of the Rheumatic Diseases. 80. 1170–1171. 1 indexed citations
8.
Pozzilli, Paolo, Emanuele Bosi, Deborah T. Cirkel, et al.. (2020). Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 105(6). e2192–e2206. 24 indexed citations
9.
Volkmann, Ingo, et al.. (2020). Erfahrungen von Aggression und Gewalt gegen Augenärztinnen und Augenärzte. Der Ophthalmologe. 117(8). 775–785. 1 indexed citations
10.
11.
Davis, Hannah M., Rafael Pacheco‐Costa, Emily G. Atkinson, et al.. (2017). Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell. 16(3). 551–563. 114 indexed citations
12.
Coghlan, Gerry, Nazzareno Galiè, Joan Albert Barberà, et al.. (2016). Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases. 76(7). 1219–1227. 109 indexed citations
13.
Hoeper, Marius M., Vallerie V. McLaughlin, Joan Albert Barberà, et al.. (2016). Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. The Lancet Respiratory Medicine. 4(11). 894–901. 49 indexed citations
14.
Galiè, Nazzareno, Joan Albert Barberà, Adaani Frost, et al.. (2015). Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine. 373(9). 834–844. 750 indexed citations breakdown →
15.
16.
Clotet, Bonaventura, Judith Feinberg, Jan van Lunzen, et al.. (2014). Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. The Lancet. 383(9936). 2222–2231. 350 indexed citations breakdown →
17.
Hughes, Sara, et al.. (2012). The statistician's role in the prevention of missing data. Pharmaceutical Statistics. 11(5). 410–416. 10 indexed citations
18.
Kim, H. Nina, et al.. (2008). Does Frequency of Genital Herpes Recurrences Predict Risk of Transmission? Further Analysis of the Valacyclovir Transmission Study. Sexually Transmitted Diseases. 35(2). 124–128. 11 indexed citations
19.
20.
Warren, Terri, Julia Harris, & Clare Brennan. (2004). Efficacy and Safety of Valacyclovir for the Suppression and Episodic Treatment of Herpes Simplex Virus in Patients with HIV. Clinical Infectious Diseases. 39(s5). S258–S266. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adriano Pellicelli Breakdown of academic impact, for papers by Katsuyuki Fukutake Breakdown of academic impact, for papers by Rachid Agher Breakdown of academic impact, for papers by Corentin Richard Breakdown of academic impact, for papers by H Beaufils Breakdown of academic impact, for papers by A Cipriani Breakdown of academic impact, for papers by Stefania Cocchi Breakdown of academic impact, for papers by William E. Beschorner Breakdown of academic impact, for papers by Maureen Reiner Breakdown of academic impact, for papers by Jean-Paul Battesti
Rankless by CCL
2026